Analysis of 300 patients with advanced NSCLC from the Network Oncology registry revealed that adding V. album to PD-1/PD-L1 inhibitor therapy doubled median overall survival from 6.8 to 13.8 months (p = 0.005), with three-year survival rates increasing from 8.0% to 16.5% [84]. Here, CD274 is linked to non-small cell lung carcinoma.